3 Further information

Guidance

Sources of evidence
Information for patients

3 Further information

3.1

NICE has published technology appraisal guidance on temozolomide for the treatment of recurrent malignant glioma (brain cancer) and carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma, and a cancer service guideline on improving outcomes for people with brain and other central nervous system tumours.

Sources of evidence

The evidence considered by the Interventional Procedures Advisory Committee is described in the overview.

Information for patients

NICE has produced information for the public on this procedure. It explains the nature of the procedure and the guidance issued by NICE, and has been written with patient consent in mind.

ISBN: 978-1-4731-6299-0